BiOCURA-metabolomic profiles and clinical parameters

Patients were selected from the observational BiOCURA study in which patients were enrolled between 2009 and 2015. Serum samples from selected subjects were measured on three targeted LC-MS platforms, covering a broad spectrum of pre-defined metabolites. The lipid platform targets low abundance lipid species, including free fatty acids (FAs) and phospholipid derivates, such as lysophosphatidylcholines (LPCs) and lysophosphatidylethanolamines (LPEs); the oxylipins platform covers oxygenated metabolites derived from polyunsaturated fatty acids through enzymatic and non-enzymatic oxidation processes; the amine platform targets amino acids and biogenic amines.Demographic, clinical, and laboratory parameters of patients at baseline were obtained, including age, gender, menopausal status, body mass index (BMI), disease duration, any previously used bDMARD (biological naivety), currently used csDMARDs and non-anti-rheumatic drugs, 28 tender joint count (TJC), 28 swollen joint count (SJC), a 100mm visual analogue scale on general health (VAS-GH), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), and anti-citrullinated protein antibody (ACPA). Disease activity was assessed at baseline and at follow-up visits, using DAS28 (disease activity score based on a 28-joint count) to evaluate therapeutic responses.